Physician profile

Leo Simpson

Advanced Heart Failure and Transplant Cardiology · Houston, TX

NPI 1922019967

$29,796.79

in general payments reported to CMS, 2019-2025

27 companies · $155 in 2025

The $155 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,176.39
Travel and Lodging$1,049.34

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abiomed $13,592.15 2019-2023 Impella
Abbott Laboratories $10,132.47 2019-2025 Diamondback Coronary, Heartmate Touch, Cardiomems
Edwards Lifesciences Corporation $1,915.43 2021-2024 Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal, Sapien 3 Ultra Resilia
Medtronic, INC. $894.34 2021-2025 Symplicity G3
Medtronic Vascular, INC. $711.37 2019-2020
Cardiovascular Systems INC. $526.78 2019-2023 Diamondback Coronary
Cardiva Medical, INC. $525.26 2023-2024 Cardiva Vascade 5f Vcs, Savvywire, Cardiva Vascade Mvp Vvcs 6-12f
Boston Scientific Corporation $510.51 2019-2024 Watchman Access System, Watchman Flx
Irhythm Technologies, INC. $153.46 2024 Zio Monitor, Zio Xt Patch
Amgen INC. $109.27 2022-2024 Repatha
Novartis Pharmaceuticals Corporation $97.60 2021-2025
Lexicon Pharmaceuticals, INC. $83.96 2023-2024 Inpefa
Inari Medical, INC. $72.62 2019
Veryan Medical Incorporated $71.43 2024 Biomimics 3d Vascular Stent System
Heartflow, INC. $50.95 2024
Show all 27 companies
CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $46.70 2021-2023 Farxiga
Scpharmaceuticals INC. $43.03 2023-2024
Novo Nordisk INC $39.01 2023-2024 Wegovy, Ozempic
Merck Sharp & Dohme LLC $38.14 2023-2025 Verquvo
Analog Devices INC. $32.66 2025 Sensinel Cpm Wearable
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $30.96 2024-2025 Lifevest
Boehringer Ingelheim Pharmaceuticals, INC. $26.59 2024 Jardiance
Baxter Healthcare $23.37 2024 Hillrom - Carnation Ambulatory Monitor
Pfizer INC. $19.51 2023
Impulse Dynamics (USA) INC. $18.83 2021
Avinger INC. $15.26 2020
W. L. Gore & Associates, INC. $15.13 2023 Gore Cardioform Septal Occluder

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$165.96 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Leo Simpson

$29,796.79

in general payments reported 2019-2025

Years
2019-2025
Top company
Abiomed
Context
The $155 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).

https://glasscript.com/doctor/314352/leo-simpson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.